Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
- PMID: 36159252
- PMCID: PMC9500479
- DOI: 10.3389/fpubh.2022.989337
Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
Abstract
In order to curb the rapid dissemination of the B.1.351 variant of SARS-CoV-2 in the district of Schwaz and beyond, the EU allocated additional vaccine doses at the beginning of March 2021 to implement a rapid mass vaccination of the population (16+). The aim of our study was to determine the seroprevalence of SARS-CoV-2 among the adult population in the district of Schwaz at the time of the implementation. Data on previous history of infections, symptoms and immunization status were collected using a structured questionnaire. Blood samples were used to determine SARS-CoV-2 specific anti-spike, anti-nucleocapsid and neutralizing antibodies. We recruited 2,474 individuals with a median age (IQR) of 42 (31-54) years. Using the official data on distribution of age and sex, we found a standardized prevalence of undocumented infections at 15.0% (95% CI: 13.2-16.7). Taken together with the officially documented infections, we estimated that 24.0% (95% CI: 22.5-25.6) of the adult population had prior SARS-CoV-2 infection. Hence, the proportion of undocumented infections identified by our study was 55.8% (95% CI: 52.7-58.5). With a vaccination coverage of 10% among the adults population at that time, we imply that a minimum of two-thirds of the target popuation was susceptible to the circulating threat when this unique campaign started.
Keywords: Comirnaty; SARS-CoV-2; anti-N; beta; seropositivity; seroprevalence; undocumented infection; vaccination.
Copyright © 2022 Willeit, Kimpel, Winner, Harthaller, Schäfer, Bante, Falkensammer, Rössler, Riepler, Ower, Sacher, von Laer and Borena.
Conflict of interest statement
DB declares to hold stocks of Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
-
- European Center For Disease Prevention Control,. Rapid Risk Assessment: SARS-CoV-2 – increased circulation of variants of concern vaccine rollout in the EU/EEA, 14th update. (2021). Available online at: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-covid-19-14... (accessed November, 2021).
-
- AGES Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH,. SARS-CoV-2-Varianten in Österreich. (2022). Available online at: https://www.ages.at/en/topics/pathogenic-organism/coronavirus/SARS-CoV-2... (accessed May, 2021).
-
- AGES . Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH. SARS-CoV-2-Varianten in Österreich. (2022). Available online at: https://www.ages.at/themen/krankheitserreger/coronavirus/SARS-CoV-2-vari... (accessed May, 2021).
-
- Gesundheitsministerium Österreich,. Impflage. (2022). Available online at: https://info.gesundheitsministerium.at/impflage (accessed June, 2022).
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous